BriaCell Therapeutics Corp.
| NASDAQ: BCTX | Healthcare / Biotechnology / Canada |
| 5.53 | -0.1900 | -3.32% | Vol 1.39M | 1Y Perf -22.71% |
| Jun 14th, 2021 16:00 DELAYED |
| BID | 5.53 | ASK | 5.62 | ||
| Open | 5.79 | Previous Close | 5.72 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 41.68M | Earnings Rating | — | |
| Price Range Ratio 52W % | 43.94 | Earnings Date | 5th Jul 2021 |
Today's Price Range 5.355.79 | 52W Range 2.819.00 | 5 Year PE Ratio Range -3.50-3.00 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 7.38% | ||
| 1 Month | 75.00% | ||
| 3 Months | 37.91% | ||
| 6 Months | 27.86% | ||
| 1 Year | -22.71% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -2 069.31 | |||
ROE last 12 Months | 59.50 | |||
ROA (5Y Avg) | -710.89 | |||
ROA last 12 Months | -370.57 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.20 | ||||
| - | ||||
| - | ||||
| - | ||||
| -120.00 | ||||
| -0.89 | ||||
| -16.73 | ||||
| -0.56 | ||||
| 56.61M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.10 | ||||
| - | ||||
| - | ||||
| -21.00 | ||||
| Leverage Ratio | -0.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | - | -0.58 | - |
| Q02 2020 | - | -1.99 | - |
| Q03 2019 | - | -0.01 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 5th Jul 2021 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.39M |
| Shares Outstanding | 7.54M |
| Trades Count | 6.04K |
| Dollar Volume | 3.50M |
| Avg. Volume | 2.57M |
| Avg. Weekly Volume | 3.15M |
| Avg. Monthly Volume | 9.29M |
| Avg. Quarterly Volume | 3.73M |
BriaCell Therapeutics Corp. (NASDAQ: BCTX) stock closed at 5.53 per share at the end of the most recent trading day (a -3.32% change compared to the prior day closing price) with a volume of 1.42M shares and market capitalization of 41.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. BriaCell Therapeutics Corp. CEO is William Williams.
The one-year performance of BriaCell Therapeutics Corp. stock is -22.71%, while year-to-date (YTD) performance is 32.61%. BCTX stock has a five-year performance of %. Its 52-week range is between 2.81 and 9, which gives BCTX stock a 52-week price range ratio of 43.94%
BriaCell Therapeutics Corp. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -370.57%, a ROC of -% and a ROE of 59.50%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BriaCell Therapeutics Corp., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BriaCell Therapeutics Corp.’s next earnings report date is 05th Jul 2021.
The consensus rating of Wall Street analysts for BriaCell Therapeutics Corp. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for BriaCell Therapeutics Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BriaCell Therapeutics Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BriaCell Therapeutics Corp. has a Buy technical analysis rating based on Technical Indicators (ADX : 58.76, ATR14 : 0.75, CCI20 : 77.25, Chaikin Money Flow : -0.59, MACD : 0.64, Money Flow Index : 89.39, ROC : 81.59, RSI : 64.67, STOCH (14,3) : 45.33, STOCH RSI : 0.20, UO : 39.97, Williams %R : -54.67), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BriaCell Therapeutics Corp. in the last 12-months were:
BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
CEO: William Williams
Telephone: +1 604 921-1810
Address: 235 - 15th Street, Vancouver V7T 2X1, BC, CA
Number of employees: 0
